The COVID-19 Student Stress Questionnaire: Validation in Spanish university students from health sciences

This study aimed to validate the Spanish version of the COVID-19 Student Stress Questionnaire (CSSQ), a 7-item tool assessing COVID-19-related stressors among university students, namely, Relationships and Academic Life, Isolation, and Fear of Contagion. Participants were 331 Spanish university students. Factor analyses sustained the three factor solution of the original tool. Data also revealed satisfactory convergent and discriminant validity, suitable internal consistency, and significant associations with psychological symptoms, as measured by the Symptom Checklist-90-Revised. The Spanish version of the CSSQ represents a valid tool to be used in clinical settings to timely identify students at high psychological risk and to develop evidence-based interventions during/after the pandemic

Characterizing HR3549B using SPHERE

Aims. In this work, we characterize the low mass companion of the A0 field star HR3549. Methods. We observed HR3549AB in imaging mode with the the NIR branch (IFS and IRDIS) of SPHERE@VLT, with IFS in YJ mode and IRDIS in the H band. We also acquired a medium resolution spectrum with the IRDIS long slit spectroscopy mode. The data were reduced using the dedicated SPHERE GTO pipeline, purposely designed for this instrument. We employed algorithms such as PCA and TLOCI to reduce the speckle noise. Results. The companion was clearly visible both with IRDIS and IFS.We obtained photometry in four different bands as well as the astrometric position for the companion. Based on our astrometry, we confirm that it is a bound object and put constraints on its orbit. Although several uncertainties are still present, we estimate an age of ~100-150 Myr for this system, yielding a most probable mass for the companion of 40-50MJup and T_eff ~300-2400 K. Comparing with template spectra points to a spectral type between M9 and L0 for the companion, commensurate with its position on the color-magnitude diagram.Comment: Accepted by A&A, 13 pages, 10 Figures (Figures 9 and 10 degraded to reduce the dimension

Detection of antihydrogen annihilations with a Si-micro-strip and pure CsI detector

In 2002, the ATHENA collaboration reported the creation and detection of cold (~15 K) antihydrogen atoms [1]. The observation was based on the complete reconstruction of antihydrogen annihilations, simultaneous and spatially correlated annihilations of an antiproton and a positron. Annihilation byproducts are measured with a cylindrically symmetric detector system consisting of two layers of double sided Si-micro-strip modules that are surrounded by 16 rows of 12 pure CsI crystals (13 x 17.5 x 17 mm^3). This paper gives a brief overview of the experiment, the detector system, and event reconstruction. Reference 1. M. Amoretti et al., Nature 419, 456 (2002).Comment: 7 pages, 5 figures; Proceedings for the 8th ICATPP Conference on Astroparticle, Particle, Space Physics, Detectors and Medical Physics Applications (Como, Italy October 2003) to be published by World Scientific (style file included

ATHENA -- First Production of Cold Antihydrogen and Beyond

Atomic systems of antiparticles are the laboratories of choice for tests of CPT symmetry with antimatter. The ATHENA experiment was the first to report the production of copious amounts of cold antihydrogen in 2002. This article reviews some of the insights that have since been gained concerning the antihydrogen production process as well as the external and internal properties of the produced anti-atoms. Furthermore, the implications of those results on future prospects of symmetry tests with antimatter are discussed.Comment: Proc. of the Third Meeting on CPT and Lorentz Symmetry, Bloomington (Indiana), USA, August 2004, edited by V. A. Kostelecky (World Scientific, Singapore). 10 pages, 5 figures, 1 table. Author affiliations cor

Cold-Antimatter Physics

The CPT theorem and the Weak Equivalence Principle are foundational principles on which the standard description of the fundamental interactions is based. The validity of such basic principles should be tested using the largest possible sample of physical systems. Cold neutral antimatter (low-energy antihydrogen atoms) could be a tool for testing the CPT symmetry with high precision and for a direct measurement of the gravitational acceleration of antimatter. After several years of experimental efforts, the production of low-energy antihydrogen through the recombination of antiprotons and positrons is a well-established experimental reality. An overview of the ATHENA experiment at CERN will be given and the main experimental results on antihydrogen formation will be reviewed.Comment: Proceedings of the XLIII International Meeting on Nuclear Physics, Bormio (Italy), March 13-20 (2005). 10 pages, 4 figures, 1 tabl

A Circumplanetary Disk around PDS70c

International audiencePDS 70 is a unique system in which two protoplanets, PDS 70 b and c, have been discovered within the dust-depleted cavity of their disk, at ~22 and 34 au, respectively, by direct imaging at infrared wavelengths. Subsequent detection of the planets in the Hα line indicates that they are still accreting material through circumplanetary disks. In this Letter, we present new Atacama Large Millimeter/submillimeter Array (ALMA) observations of the dust continuum emission at 855 μm at high angular resolution (~20 mas, 2.3 au) that aim to resolve the circumplanetary disks and constrain their dust masses. Our observations confirm the presence of a compact source of emission co-located with PDS 70 c, spatially separated from the circumstellar disk and less extended than ~1.2 au in radius, a value close to the expected truncation radius of the circumplanetary disk at a third of the Hill radius. The emission around PDS 70 c has a peak intensity of ~86 ± 16 μJy beam-1, which corresponds to a dust mass of ~0.031 M⊕ or ~0.007 M⊕, assuming that it is only constituted of 1 μm or 1 mm sized grains, respectively. We also detect extended, low surface brightness continuum emission within the cavity near PDS 70 b. We observe an optically thin inner disk within 18 au of the star with an emission that could result from small micron-sized grains transported from the outer disk through the orbits of b and c. In addition, we find that the outer disk resolves into a narrow and bright ring with a faint inner shoulder

the gatto study a phase i of the anti egfr tomuzotuximab to in combination with the anti muc1 gatipotuzumab gat in patients with egfr positive solid tumors

n/

Clinical, pathological, and prognostic features of rare BRAF mutations in metastatic colorectal cancer: a bi-institutional retrospective analysis (REBUS study)

n/

Maintenance therapy of patients with recurrent epithelial ovarian carcinoma with the anti-tumor-associated-mucin-1 antibody gatipotuzumab: results from a double-blind, placebo-controlled, randomized, phase II study

BACKGROUND: Gatipotuzumab is a humanized monoclonal antibody recognizing the carbohydrate-induced epitope of the tumor-associated mucin-1 (TA-MUC1). This study aimed to evaluate the efficacy and safety of switch maintenance therapy with gatipotuzumab in patients with TA-MUC1-positive recurrent ovarian, fallopian tube, or primary high-grade serous peritoneal cancer. PATIENTS AND METHODS: In this double-blind, randomized, placebo-controlled, phase II trial, patients with at least stable disease (SD) following chemotherapy were randomized 2:1 to receive intravenous gatipotuzumab (500 mg followed by 1700 mg 1 week later) or placebo every 3 weeks until tumor progression or unacceptable toxicity occurred. Stratification factors were the number of prior chemotherapy lines (2 versus 3-5), response versus SD after the most recent chemotherapy, and progression-free survival (PFS) <6 versus 6-12 months following the prior therapy. Primary endpoint was PFS according to modified immune-related RECIST 1.1 response criteria. Secondary endpoints were PFS at 6 months, safety, overall response rate, CA-125 progression, overall survival, quality of life, and pharmacokinetics. RESULTS: Overall, 216 patients were randomized to gatipotuzumab (n  =  151) or placebo (n  =  65). Median PFS with gatipotuzumab was 3.5 months as compared with 3.5 months with placebo (hazard ratio 0.96, 95% confidence interval 0.69-1.33, P  =  0.80). No advantage for gatipotuzumab over placebo was seen in the secondary efficacy endpoints or in any stratified subgroups. Gatipotuzumab was well tolerated, with mild to moderate infusion-related reactions being the most common adverse events. CONCLUSIONS: Gatipotuzumab switch maintenance therapy does not improve outcome in TA-MUC1-positive ovarian cancer patients. TRIAL REGISTRATION: ClinicalTrials.govNCT01899599; https://clinicaltrials.gov/ct2/show/NCT01899599